The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy)

Abstract

MDMA (3-4-methylenedioxymethamphetamine, commonly known as Ecstasy) is a potent mechanism-based inhibitor (MBI) of cytochrome P450 2D6 (CYP2D6), causing quasi-irreversible inhibition of the enzyme in vitro. An evaluation of the in vivo implications of this phenomenon depends on the accuracy of the estimates of the parameters that define the inhibition in vitro, namely kinact (the maximal inhibition rate) and KI (the inactivation constant). These values are determined in two steps, pre-incubation of the enzyme with the inhibitor (enzyme inactivation), followed by dilution and further incubation to measure residual enzyme activity with a probe substrate. The aim of this study was to assess the impact of different dilutions and probe substrate concentrations on the estimates of kinact and KI using recombinantly expressed CYP2D6. Enzyme activity was measured by the conversion of dextromethorphan (DEX) to dextrorphan (DOR). Dilution factors of 1.25, 2, 5, 10, 25 and 50 (DEX at 30µM) gave mean (±SE) values of kinact (min 1) of 0.20±0.06, 0.21±0.05, 0.31±0.06, 0.37±0.11, 0.51±0.10 and 0.58±0.08, respectively, and KI (µM) values (after correction for non-specific microsomal binding) of 2.22±1.90, 2.80±1.34, 5.78±2.07, 6.36±2.93, 3.99±1.57 and 4.86±1.37, respectively. Accordingly, high (e.g. 50 fold) and low (e.g. 1.25 fold) dilutions were associated with statistically significant differences in kinetic values (p <0.05). Varying DEX concentration (10–100µM) was not associated with significant changes in kinact and K values when a five-fold dilution was used (with the exception of a lower KI at 10µM DEX). High dilution was also shown to reduce non-specific microsomal binding of MDMA. The changes in the two kinetic parameters were dependent on the experimental procedure and shown to be unlikely to have a material influence on the maximum inhibition of CYP2D6 expected in vivo after typical recreational doses of MDMA (50–100mg), since the potency of inhibition was high. The different values of the kinetic parameters were predicted to have a marginal influence on the time for recovery of enzyme activity following re-synthesis of CYP2D6.

Keywords

MDMA Ecstasy mechanism-based enzyme inhibition CYP2D6

Get full access to this article

View all access options for this article.

References

Ching M S , Blake C L , Ghabrial H , Ellis S W , Lennard M S , Tucker G T , Smallwood R A (1995) Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites . Biochem Pharm 50: 833–837 .

Davies B , Morris T (1993) Physiological parameters in laboratory animals and humans . Pharm Res 10: 1093–1095 .

Delaforge M , Jaouen M , Bouille G (1999) Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP2D . Environmental Toxicology and Pharmacology 7: 153–158 .

de la Torre R , Farre M , Ortuno J , Mas M , Brenneigen R , Roset P N , Segura J , Cami J (2000) Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans . Br J Clin Pharmacol 49: 104–109 .

Ellis S W , Ching M S , Watson P F , Henderson C J , Simula A P , Lennard M S , Tucker GT , Woods H F (1992) Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast . Biochem Pharm 44: 617–620 .

Ghanbari F , Rowland-Yeo K , Bloomer J C , Clarke S E , Lennard M S , Tucker G T , Rostami-Hodjean A (2006) A critical evaluation of the experimental design of studies of mechanism-based inhibition studies and the assessment of their implications for in vitro–in vivo extrapolation . Curr Drug Metab 7: 315–334 .

Heydari A , Rowland Yeo K , Lennard M S , Ellis S W , Tucker G T , Rostami-Hodjegan A (2004) Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphethamine Drug Metab Dispos 32: 1213–1217 .

Jacqz-Aigrain E , Menard Y , Popon M , Mathieu H (1989) Dextromethorphan phenotypes determined by high-performance liquid chromatography and fluorescence detection J Chromatogr 495: 361–363 .

Kreth K P , Kovar K A , Schwab M , Zanger U M (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of ‘Ecstasy’-related designer drugs . Biochem Pharm 59: 1563–1571 .

10.

Lin L Y , Di Stefano E W , Schmitz D A , Hsu L , Ellis S W , Lennard M S , Tucker G T , Cho A K (1997) Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6 . Drug Metab Dispos 25: 1059–1064 .

11.

Liston H L , DeVane L , Boulton D W , Risch S C , Markowitz J S , Goldman J (2002) Differential time course of cytochrome P4502D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers . J Clin Psychopharm 22: 169–173 .

12.

Lowry O , Rosebrough N , Farr A , Randall R (1951) Protein measurements with the folin phenol reagent . J Biol Chem 193: 265–275 .

13.

Omura T , Sato R (1964) The carbon monoxide-binding pigment of liver microsomes: evidence for its hemoprotein nature . J Biol Chem 236: 2370–2378 .

14.

Ramamoorthy Y , Yu A M , Suh N , Haining R L , Tyndale R F , Sellers E M (2002) Reduced (+/-)-3,4-methylenedioxymethamphetamine (‘ecstasy’) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro . Biochem Pharm 63: 2111–2119 .

15.

Renwick A B , Watts P S , Edwards R J , Barton P T , Guyonnet I , Price R J , Tredger J M , Pelkonen O , Boobis A R , Lake B G (2000) Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices . Drug Metab Dispos 28: 1202–1209 .

16.

Rostami-Hodjegan A , Tucker G T (2004) ‘ In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug–drug interactions . Drug Discovery Today: Technology 1: 441–448 .

17.

Silverman R B (1998) Mechanism-based Enzyme Inactivation. In Chemistry and Enzymology. Vol 1. CRC Press Inc., Boca Raton, Florida .

18.

Tucker G T , Lennard M S , Ellis S W , Woods H F , Cho A K , Lin L Y , Hiratsuka A , Schmitz D A , Chu T Y (1994) The demethylentation of methylenedioxymethamphetamine (‘ecstasy’) by debrisoquine hydroxylase (CYP2D6) . Biochem Pharm 47: 1151–1156 .

19.

Venkatakrishnan K , Obach R S (2005) In vitro–in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude . Drug Metab Dispos 33: 845–852 .